FDA Approves First Drug for GVHD After Stem Cell Transplant – Medscape
Medscape |
FDA Approves First Drug for GVHD After Stem Cell Transplant
Medscape In a first, the US Food and Drug Administration (FDA) has approved a drug for use in patients who develop the life-threatening condition of chronic graft-vs-host disease (cGVHD) after having undergone a hematopoietic stem cell transplant (HSCT). FDA approves treatment for chronic graft versus host disease Imbruvica approved as first therapy for chronic graft-vs-host disease FDA Approves First Treatment for Chronic Graft Versus Host Disease |
